Cardiovascular disease remains the leading cause of mortality worldwide. Semaglutide, a GLP-1 receptor agonist, has shown cardiovascular benefits, but its safety profile, including risks of various adverse events, in adults with established atherosclerotic cardiovascular disease (ASCVD) requires systematic evalua...
K. Keswani, M. Reddy, A. Aslam et al.· European Heart Journal· 0 citations
Acute heart failure (HF) patients are at high risk, especially in the first three months following discharge, when rehospitalizations are 30% common and mortality can be close to 10%. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential for treating heart failure, their benefit when initiated...
N. Shafi, F. Khalid, M. Elshabrawi et al.· European Heart Journal· 0 citations
Transradial access has revolutionized interventional cardiology by reducing vascular complications compared to femoral approaches. However, as novel techniques emerge, comprehensive quantitative synthesis comparing these methodologies remains limited, creating uncertainty regarding the optimal procedural strategy...
K. Keswani, H. Saqib, T. Khan et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.